Name: 1-Methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazoleIn 2022 ,《Discovery of an Orally Bioavailable and Selective PKMYT1 Inhibitor, RP-6306》 appeared in Journal of Medicinal Chemistry. The author of the article were Szychowski, Janek; Papp, Robert; Dietrich, Evelyne; Liu, Bingcan; Vallee, Frederic; Leclaire, Marie-Eve; Fourtounis, Jimmy; Martino, Giovanni; Perryman, Alexander L.; Pau, Victor; Yin, Shou Yun; Mader, Pavel; Roulston, Anne; Truchon, Jean-Francois; Marshall, C. Gary; Diallo, Mohamed; Duffy, Nicole M.; Stocco, Rino; Godbout, Claude; Bonneau-Fortin, Alexanne; Kryczka, Rosie; Bhaskaran, Vivek; Mao, Daniel; Orlicky, Stephen; Beaulieu, Patrick; Turcotte, Pascal; Kurinov, Igor; Sicheri, Frank; Mamane, Yael; Gallant, Michel; Black, W. Cameron. The article conveys some information:
PKMYT1 is a regulator of CDK1 phosphorylation and is a compelling therapeutic target for the treatment of certain types of DNA damage response cancers due to its established synthetic lethal relationship with CCNE1 amplification. To date, no selective inhibitors have been reported for this kinase that would allow for investigation of the pharmacol. role of PKMYT1. To address this need compound 1 was identified as a weak PKMYT1 inhibitor. Introduction of a dimethylphenol increased potency on PKMYT1. These dimethylphenol analogs were found to exist as atropisomers that could be separated and profiled as single enantiomers. Structure-based drug design enabled optimization of cell-based potency. Parallel optimization of ADME properties led to the identification of potent and selective inhibitors of PKMYT1. RP-6306 inhibits CCNE1-amplified tumor cell growth in several preclin. xenograft models. The first-in-class clin. candidate RP-6306 is currently being evaluated in Phase 1 clin. trials for treatment of various solid tumors. In the part of experimental materials, we found many familiar compounds, such as 1-Methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole(cas: 847818-74-0Name: 1-Methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole)
1-Methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole(cas: 847818-74-0) belongs to pyrazoles. Pyrazoles are commonly used scaffold molecules in drug discovery projects. The use of pyrazole derivatives is based on their analgesic, monoamine oxidase inhibitory, anti-inflammatory, antipyretic, neuroleptic, anticonvulsant, antiarrhythmic, sedative, muscle relaxant, antidiabetic and antibacterial activities. Name: 1-Methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole
Referemce:
Pyrazole – Wikipedia,
Pyrazoles – an overview | ScienceDirect Topics